Abstract library

14 results for "irinotecan".
#2864 Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Camilla Bardasi
Authors: Bardasi C, Caputo F, Santini C, Cerma K, ...
#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System
Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Clinical cases/reports
Presenting Author: MD Tomohiro Yamaguchi
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#139 Association of carcinoid with noncarcinoid neoplasms
Introduction: Carcinoid tumors have a complex disease spectrum. Most have a benign clinical course, but some are aggressive, with invasive growth, metastasis and short survival. In carcinoid tumors, more than 20% are associated with noncarcinoid neoplasms. When the second tumor is a more malignant lesion, the prognosis usually is correlated more closely with the noncarcinoid malignant neoplasm.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Joao C Ribeiro
#597 Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports
Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Shoichi Nakazuru
#910 Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia
Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Alexander Kuzminov
#939 Large Cell Neuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review
Introduction: Primary large cell neuroendocrine carcinoma (LCNEC) of the gallbladder is rare. The standard treatment for gallbladder NEC with liver metastases has not been established, but combination chemotherapy with etoposide plus cisplatin (EP) is recommended for NEC patients with liver metastasis, regardless of the primary tumor site.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
Authors: Nakazuru S, Kimura K, Tada Y, Iwasaki R, ...
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
#1724 Outcomes of Hepatobiliary Neuroendocrine Neoplasms Treated with Systemic Therapy: A Retrospective Analysis.
Introduction: Primary hepatobiliary neuroendocrine neoplasms (NEN) are rare. Knowledge about clinicopathological findings and treatment results of hepatobiliary NEN is limited.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Komiyama Satoshi